Thursday 16 October, 2025
Because clinical data is often limited in the number of patients or observations per patient, PK/PD analyses that don’t model the…
Read moreOral: Modelling using Bayesian Analysis
Application of a Bayesian population approach to physiologically-based modelling and simulation of mavoglurant pharmacokinetics
Thursday 16 October, 2025
Objectives: Mavoglurant (MVG) is an antagonist at the metabotropic glutamate receptor 5 currently under clinical development at Novartis Pharma AG…
Read morePart II: Building Robust PK/PD Population Models with Bayesian Inference
Thursday 16 October, 2025
Because clinical data is often limited in the number of patients or observations per patient, PK/PD analyses that don’t model the…
Read more